Review
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2022; 14(5): 885-895
Published online May 27, 2022. doi: 10.4254/wjh.v14.i5.885
Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma
Kylie E Zane, Paul B Nagib, Sajid Jalil, Khalid Mumtaz, Mina S Makary
Kylie E Zane, Paul B Nagib, College of Medicine, The Ohio State University, Columbus, OH 43210, United States
Sajid Jalil, Khalid Mumtaz, Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States
Mina S Makary, Division of Vascular and Interventional Radiology, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States
Author contributions: All authors contributed to the preparation of the manuscript.
Conflict-of-interest statement: The authors declare they have no conflicts of interest
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mina S Makary, MD, Assistant Professor, Attending Doctor, Director, Division of Vascular and Interventional Radiology, Department of Radiology, The Ohio State University Wexner Medical Center, 395 W. 12th Ave, 4th Floor, Columbus, OH 43210, United States. mina.makary@osumc.edu
Received: December 22, 2021
Peer-review started: December 22, 2021
First decision: February 8, 2022
Revised: February 20, 2022
Accepted: April 25, 2022
Article in press: April 25, 2022
Published online: May 27, 2022
Processing time: 153 Days and 3.9 Hours
Core Tip

Core Tip: Accepted curative modalities for early hepatocellular carcinoma (HCC) include resection, liver transplant, and loco-regional therapies. In this manuscript, we review the curative-intent loco-regional therapies including recent evidence from the LEGACY study and DOSISPHERE trial demonstrating a curative role for transarterial radio-embolization in early HCC.